Proven, effective & superior
Renaissance Wave™ Therapy
Beyond What Pills Can Do on Their Own
Renaissance Wave™ Therapy is low-intensity extracorporeal shock wave therapy (LI-ESWT) focused ultrasound that treats erectile dysfunction.
Renaissance Wave Therapy improved penile blood flow in men to improve erectile function.
Proven, non-invasive, comfortable, and effective.
Scientifically studied worldwide in many clinical trials over the past 10+ years.vii
The Renaissance Wave™ Therapy Difference
Increases blood circulation, vasodilation, and the growth of new blood vessels (neovascularization).i
These long-term results have been proven in many clinical trials. There’s no need for surgery, drugs, or pain management.iv
Renaissance Wave Therapy enables a targeted, deeper, pain-free treatment where it counts.
Single, focused pulses that can treat down to the cellular level.
Radial shock wave treatments offered by other providers can be painful, require local anesthesia, and haven’t been proven effective.
The radial energy is scattered and doesn’t reach the targeted area for maximum efficacy.
What You Can Expect
Set a time for an online appointment that works for you.
Tell Us What You Need
Answer a few questions about your symptoms and health with our medical provider during your in-office consultation, or in your secure, HIPAA protected, and private patient portal prior to your telemedicine consultation.
Meet Your Provider
When it is time for your consultation appointment, you will meet with our team in our clinic or via telemedicine based on your preference and choice when booking your visit.
Begin Your Renaissance Wave™ Therapy
If approved for Renaissance Wave therapy (LI-ESWT) treatments, we will schedule you for six 20-minute in-office sessions over an average of a six-week period. You can resume normal activities immediately after each treatment.
Ready to start your visit?
Learn more about how Renaissance Wave can improve your life. Book an appointment today!
Renaissance Wave Therapy FAQs
Renaissance Wave therapy (LI-ESWT) utilizes highly specialized sound waves that can be specifically targeted to a treatment area within the body. Shockwave therapy dates to the 1980s when it was first used to treat kidney stonesvii. Since then, the technology has gone through many developmental milestones and has treated millions of people with various conditions.
While many physicians are familiar with erectile dysfunction and its symptoms, Revibe Men’s Health specializes in ED treatments and treatments like Renaissance Wave treatment. They have successfully treated thousands of men suffering from ED. Revibe Men’s Health prides itself on a professional, discreet, and confidential environment.
Most patients say it feels like a light tapping or tingling sensation and they do not experience pain.
Confidentiality is important at Revibe Men’s Health. When you arrive and check-in you will be escorted to a treatment room to limit your waiting time in the lobby. Your Renaissance Wave™ therapy will be administered by a member of the medical team. The shockwave wand will be directed to specific treatment areas around the shaft and base of the penis as identified by the medical team member. Typically, treatment sessions will last about 20 minutes.
Renaissance Wave therapy is a simple in-office procedure. The treatment (based on proven trials) lasts about 20 minutes. The typical shockwave patient will have six treatment appointments. Your healthcare provider will determine the best treatment schedule for you.
Currently, insurance companies are not covering shockwave therapy for ED. However, patients using an HSA (Health Savings Account program) should be able to submit their treatment for approval as an HSA expense or use their HSA credit/debit card to pay for services.
Revibe Men’s Health does not work directly with insurance carriers.
i. Gruenwald, et al, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607492/
ii. Lei, et al, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888889/
iii. Salter, et al, https://www.jsm.jsexmed.org/article/S1743-6095(20)30029-1/fulltext
iv. Kim, et al, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076310/
v. Wang, et al, https://pubmed.ncbi.nlm.nih.gov/31546912/
vi. Kim, et al, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076310/
vii. Lei, et al, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888889/
viii. Katz, et al, https://www.smr.jsexmed.org/article/S2050-0521(19)30099-X/fulltext
ix. Capogrosso, et al, https://www.jsm.jsexmed.org/article/S1743-6095(19)31320-7/fulltext
x. Vardi, et al, https://pubmed.ncbi.nlm.nih.gov/20451317/
xi. Gruenwald, et al, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607492/
xii. FDA (USA), https://www.accessdata.fda.gov/cdrh_docs/pdf8/P080028b.pdf
xiii. Vardi, et al, https://pubmed.ncbi.nlm.nih.gov/20451317/